Evidence map›Paper›PMID 39054750›Full record

ArticlePharmacology research & perspectives2024

Treatment of [99mTc]Tc-hydroxy-diphosphonate ([99mTc]Tc-HDP) extravasation using hyaluronidase.

Kevin R Doornhof, Quido de Lussanet de la Sablonière, Stijn L W Koolen, Mark W Konijnenberg

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacology research & perspectives, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kevin R DoornhofDepartment of Radiology and Nuclear Medicine, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID 0009-0005-7704-8349
Quido de Lussanet de la SablonièreDepartment of Radiology and Nuclear Medicine, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID 0000-0002-9779-8682
Stijn L W KoolenDepartment of Radiology and Nuclear Medicine, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID 0000-0002-0973-7530
Mark W KonijnenbergDepartment of Radiology and Nuclear Medicine, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID 0000-0001-5895-8500

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extravasation of 99mTc-labeled radiopharmaceuticals is generally considered to require no specific intervention. In the presented case, the use of hyaluronidase could have minimized the adverse effects resulting from such an extravasation. Currently, no guidelines exist regarding the use of hyaluronidase after extravasation of [99mTc]Tc-HDP. Considering the low risk of administering hyaluronidase, it should be considered to limit the risk of injury after extravasation of [99mTc]Tc-HDP.

Indexed as

Extravasation of Diagnostic and Therapeutic MaterialsHyaluronoglucosaminidaseRadiopharmaceuticalsHumansOrganotechnetium CompoundsTechnetium Tc 99m MedronateHyaluronoglucosaminidaseOrganotechnetium CompoundsRadiopharmaceuticalstechnetium Tc 99m hydroxymethylene diphosphonateTechnetium Tc 99m Medronatebone scintigraphyextravasationradiology [99mTc]Tc‐HDP

Identifiers

PMID39054750
PMCPMC11272945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.